BlackRock Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

BlackRock Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$973K	Buy	6,901 +103	+2%	+$13.9K	﹤0.01%	2713
2016 Q3	$992K	Buy	6,798 +560	+9%	+$67.3K	﹤0.01%	2670
2016 Q2	$628K	Buy	6,238 +791	+15%	+$103K	﹤0.01%	2931
2016 Q1	$729K	Buy	5,447 +93	+2%	+$10.3K	﹤0.01%	2698
2015 Q4	$1.06M	Buy	5,354 +44	+0.8%	+$9.53K	﹤0.01%	2560
2015 Q3	$839K	Sell	5,310 -1,294	-20%	-$346K	﹤0.01%	2723
2015 Q2	$2.69M	Buy	6,604 +2,559	+63%	+$1.11M	﹤0.01%	1998
2015 Q1	$1.86M	Sell	4,045 -580	-13%	-$250K	﹤0.01%	2083
2014 Q4	$2.6M	Sell	4,625 -27	-0.6%	-$15.3K	﹤0.01%	1844
2014 Q3	$2.44M	Buy	4,652 +456	+11%	+$257K	﹤0.01%	1852
2014 Q2	$2.93M	Buy	4,196 +2,696	+180%	+$1.25M	﹤0.01%	1784
2014 Q1	$695K	Buy	1,500 +177	+13%	+$89.7K	﹤0.01%	2769
2013 Q4	$455K	Buy	+1,323	New	+$365K	﹤0.01%	2995

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Investment Management's KPTI Position: Q4 2016 in Review

BlackRock Investment Management increased its Karyopharm Therapeutics (KPTI) stake by 1.5% in Q4 2016, buying an estimated $13.9K and bringing the position to 6,901 shares worth $973K. The position accounts for ﹤0.01% of the portfolio, ranked #2713.

BlackRock Investment Management first reported a position in KPTI in Q4 2013 and has held it in 13 quarters since. The position peaked at $2.93M in Q2 2014. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

BlackRock Investment Management held 6,901 shares of Karyopharm Therapeutics worth $973K as of Q4 2016.
BlackRock Investment Management bought 103 Karyopharm Therapeutics shares in Q4 2016, an estimated $13.9K.
Karyopharm Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2713 holding.
BlackRock Investment Management first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 13 quarters since.
BlackRock Investment Management's Karyopharm Therapeutics position peaked at $2.93M in Q2 2014.
86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.